Development of nucleic acid vaccines: Use of self-amplifying RNA in lipid nanoparticles

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 1833-1843

  Rodríguez Gascón, Alicia ^a   del Pozo Rodríguez, Ana ^a   Solinís, María Ángeles ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Liposomes; Nucleic acid vaccines; RNA replicon; Self amplifying RNA vaccine; Solid lipid nanoparticles

Indexed keywords

DNA VACCINE; LIPOSOME; RNA VACCINE; SOLID LIPID NANOPARTICLE;

ADAPTIVE IMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPLEX FORMATION; COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STABILITY; HOST CELL; HUMAN; HUMORAL IMMUNITY; INNATE IMMUNITY; NANOEMULSION; NANOPHARMACEUTICS; NONHUMAN; REPLICON; REVIEW; VACCINE PRODUCTION;

LIPOSOMES; NUCLEIC ACID VACCINES; RNA REPLICON; SELF-AMPLIFYING RNA VACCINE; SOLID LIPID NANOPARTICLES;

LIPIDS; LIPOSOMES; NANOCAPSULES; NUCLEIC ACID AMPLIFICATION TECHNIQUES; RNA; VACCINES, DNA;

EID: 84898604804     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S39810     Document Type: Review

References (93)

1. Ulmer JB, Mason PW, Geall A, Mandl CW. RNA-based vaccines. Vaccine. 2012; 30(30): 4414-4418.
2. Liu MA. DNA vaccines: a review. J Intern Med. 2003; 253(4): 402-410.
3. Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 1993; 259(5102): 1745-1749.
4. Geall AJ, Mandl CW, Ulmer JB. RNA: the new revolution in nucleic acid vaccines. Semin Immunol. 2013; 25(2): 152-159.
5. Johansson DX, Ljungberg K, Kakoulidou M, Liljeström P. Intradermal electroporation of naked replicon RNA elicits strong immune responses. PLoS One. 2012; 7(1): e29732.
6. Liu MA. DNA vaccines: an historical perspective and view to the future. Inmunol Rev. 2011; 239(1): 62-84.
7. Hobo W, Novobrantseva TI, Fredrix H, et al. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. Cancer Immunol Immunother. 2013; 62(2): 285-297.
8. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990; 247(4949 Pt 1): 1465-1468.
9. Martinon F, Krishnan S, Lenzen G, et al. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol. 1993; 23(7): 1719-1722.
10. Kreiter S, Diken M, Selmi A, Türeci Ö, Sahin U. Tumor vaccination using messenger RNA: prospects of a future therapy. Curr Opin Immunol. 2011; 23(3): 399-406.
11. Rayburn ER, Zhang R. Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? Drug Discov Today. 2008; 13(11-12): 513-521.
12. Kim SS, Peer D, Kumar P, et al. RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther. 2010; 18(2): 370-376.
13. Jiang W. Blockade of B7-H1 enhances dendritic cell-mediated T-cell response and antiviral immunity in HBV transgenic mice. Vaccine. 2012; 30(4): 758-799.
14. Akita H, Kogure K, Moriguchi R, et al. Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: programmed endosomal escape and dissociation. J Control Release. 2010; 143(3): 311-317.
15. Piggott JM, Sheahan BJ, Soden DM, O'Sullivan GC, Atkins GJ. Electroporation of RNA stimulates immunity to an encoded reporter gene in mice. Mol Med Rep. 2009; 2(5): 753-736.
16. Diken M, Kreiter S, Selmi A, Türeci O, Sahin U. Antitumor vaccination with synthetic mRNA: strategies for in vitro and in vivo preclinical studies. Methods Mol Biol. 2013; 969: 235-246.
17. Pollard C, Rejman J, De Haes W, et al. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol Ther. 2013; 21(1): 251-259.
18. Weiss R, Scheiblhofer S, Roesler E, Weinberger E, Thalhamer J. mRNA vaccination as a safe approach for specific protection from type I allergy. Expert Rev Vaccines. 2012; 11(1): 55-67.
19. Jensen S, Thomsen AR. Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion. J Virol. 2012; 86(6): 2900-2910.
20. Martínez-Gil L, Goff PH, Hai R, García-Sastre A, Shaw ML, Palese P. A Sendai virus-derived RNA agonist of RIG-I as a virus vaccine adjuvant. J Virol. 2013; 87(3): 1290-1300.
21. Jin B, Sun T, Yu XH, et al. Immunomodulatory effects of dsRNA and its potential as vaccine adjuvant. J Biomed Biotechnol. 2010; 2010: 690438.
22. Pascolo S. Vaccination with messenger RNA (mRNA). Handb Exp Pharmacol. 2008; 183: 221-235.
23. Zabner J, Fasbender AJ, Moninger T, Poellinger KA, Welsh MJ. Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem. 1995; 270(32): 18997-19007.
24. Bettinger T, Carlisle RC, Read ML, Ogris M, Seymour LW. Peptide-mediated RNA delivery: a novel approach for enhanced transfection of primary and post-mitotic cells. Nucleic Acids Res. 2001; 29(18): 3882-3891.
25. Hekele A, Bertholet S, Archer J, et al. Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice. Emerging Microbes and Infections. 2013; 2: e52.
26. Jones KL, Drane D, Gowans EJ. Long-term storage of DNA-free RNA for use in vaccine studies. Biotechniques. 2007; 43(5): 675-681.
27. European Medicines Agency. Guideline on human cell-based medicinal products. London, UK: European Medicines Agency; 2007. Available from: http://www. ema. europa. eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003898. pdf.
28. European Commission. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the community code relating to medicinal products for human use: Brussels, Belgium: European Commission; 2001. Available from: http://www. ema. europa. eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004481. pdf.
29. Weide B, Carralot JP, Reese A, et al. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother. 2008; 31(2): 180-188.
30. Weide B, Pascolo S, Scheel B, et al. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother. 2009; 32(5): 498-507.
31. Xu J, Luft JC, Yi X, et al. RNA replicon delivery via lipid-complexed PRINT protein particles. Mol Pharm. 2013; 10(9): 3366-3374.
32. Kamrud KI, Coffield VM, Owens G, et al. In vitro and in vivo characterization of microRNA-targeted alphavirus replicon and helper RNAs. J Virol. 2010; 84(15): 7713-7725.
33. Diken M, Kreiter S, Selmi A, et al. Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation. Gene Ther. 2011; 18(7): 702-708.
34. Widman DG, Frolov I, Mason PW. Third-generation flavivirus vaccines based on single-cycle, encapsidation-defective viruses. Adv Virus Res. 2008; 72: 77-126.
35. Tannis LL, Gauthier A, Evelegh C, et al. Semliki forest virus and Kunjin virus RNA replicons elicit comparable cellular immunity but distinct humoral immunity. Vaccine. 2005; 23(33): 4189-4194.
36. Gehrke R, Heinz FX, Davis NL, Mandl CW. Heterologous gene expression by infectious and replicon vectors derived from tick-borne encephalitis virus and direct comparison of this flavivirus system with an alphavirus replicon. J Gen Virol. 2005; 86 Pt 4: 1045-1053.
37. Carroll TD, Matzinger SR, Barro M, et al. Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone® in rhesus macaques. Vaccine. 2011; 29(5): 931-940.
38. Bernstein DI, Reap EA, Katen K, et al. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine. 2009; 28(2): 484-493.
39. Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat Mater. 2013; 12(11): 967-977.
40. Kleinman ME, Yamada K, Takeda A, et al. Sequence-and target-independent angiogenesis suppression by siRNA via TLR3. Nature. 2008; 452(7187): 591-597.
41. Rodríguez-Gascón AR, Solinis MA, del Pozo-Rodríguez A. Non-viral delivery systems in gene therapy. In: Martin F, editor. Gene Therapy-Tools and Potential Applications. Rijeka, Croatia: Intech; 2013.
42. Gomes-da-Silva LC, Fonseca NA, Moura V, Pedroso de Lima MC, Simões S, Moreira JN. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges. Acc Chem Res. 2012; 45(7): 1163-1171.
43. Moreira JN, Santos A, Moura V, Pedroso de Lima MC, Simões S. Non-viral lipid-based nanoparticles for targeted cancer systemic gene silencing. J Nanosci Nanotechnol. 2008; 8(5): 2187-2204.
44. Vaishnaw AK, Gollob J, Gamba-Vitalo C, et al. A status report on RNAi therapeutics. Silence. 2010; 1(1): 14.
45. Zimmer G. RNA replicons-a new approach for influenza virus immunoprophylaxis. Viruses. 2010; 2(2): 413-434.
46. McCaskill J, Singhania R, Burgess M, et al. Efficient biodistribution and gene silencing in the lung epithelium via intravenous liposomal delivery of siRNA. Mol Ther Nucleic Acids. 2013; 2: e96.
47. Gascón AR, Pedraz JL. Cationic lipids as gene transfer agents: a patent review. Expert Opin Ther Patent. 2008; 18(5): 515-524.
48. Mahato RI, Kim SW, editors. Pharmaceutical Perspectives of Nucleic Acid-Based Therapeutics. London, UK: Taylor and Francis; 2002.
49. Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2007-an update. J Gene Med. 2007; 9(10): 833-842.
50. Alabi CA, Love KT, Sahay G, et al. Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery. Proc Natl Acad Sci U S A. 2013; 110(32): 12881-12886.
51. Lin PJ, Tam YY, Hafez I, et al. Influence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNA. Nanomedicine. 2013; 9(2): 233-246.
52. Yew NS, Scheule RK. Toxicity of cationic lipid-DNA complexes. Adv Genet. 2005; 53P: 189-214.
53. Puri A, Loomis K, Smith B, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst. 2009; 26(6): 523-580.
54. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005; 4(2): 145-160.
55. Markov OO, Mironova NL, Maslov MA, et al. Novel cationic liposomes provide highly efficient delivery of DNA and RNA into dendritic cell progenitors and their immature offsets. J Control Release. 2012; 160(2): 200-210.
56. Mockey M, Bourseau E, Chandrashekhar V, et al. mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes. Cancer Gene Ther. 2007; 14(9): 802-814.
57. Geall AJ, Verma A, Otten GR, et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A. 2012; 109(36): 14604-14609.
58. Kwon SM, Nam HY, Nam T, et al. In vivo time-dependent gene expression of cationic lipid-based emulsion as a stable and biocompatible non-viral gene carrier. J Control Release. 2008; 128(1): 89-97.
59. Lizinger DC, Brown JM, Wala I, et al. Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim Biophys Acta. 1996; 1281(2): 139-149.
60. Hyvonen Z, Ronkko S, Toppinen MR, Jaaskeainen I, Plotniece A, Urtti A. Dioleoyl phosphatidylethnolamine and PEG-lipid conjugates modify DNA delivery medicated by 1, 4-dihydropyridine amphiphiles. J Control Release. 2004; 99(1): 177-190.
61. Stopeck AT, Hersh EM, Akporiaye ET, et al. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol. 1997; 15(1): 341-349.
62. Stopeck AT, Jones A, Hersh EM, et al. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin Cancer Res. 2001; 7(8): 2285-2291.
63. Souto EB, Nayak AP, Murthy RS. Lipid nanoemulsions for anti-cancer drug therapy. Pharmazie. 2011; 66(7): 473-478.
64. Bruxel F, Vilela JM, Andrade MS, et al. Investigation of the structural organization of cationic nanoemulsion/antisense oligonucleotide complexes. Colloids Surf B Biointerfaces. 2013; 112: 530-536.
65. Liu CH, Yu SY. Cationic nanoemulsions as non-viral vectors for plasmid DNA delivery. Colloids Surf B Biointerfaces. 2010; 79(2): 509-515.
66. Verissimo LM, Lima LF, Egito LC, de Oliveira AG, do Egito ES. Pharmaceutical emulsions: a new approach for gene therapy. J Drug Target. 2010; 18(5): 333-342.
67. Bruxel F, Cojean S, Bochot A, et al. Cationic nanoemulsion as a delivery system for oligonucleotides targeting malarial topoisomerase II. Int J Pharm. 2011; 416(2): 402-409.
68. Nam HY, Park JH, Kim K, Kwon IC, Jeong SY. Lipid-based emulsion system as non-viral gene carriers. Arch Pharm Res. 2009; 32(5): 639-646.
69. Choi WJ, Kim JK, Choi SH, Park JS, Ahn WS, Kim CK. Low toxicity of cationic lipid-based emulsion for gene transfer. Biomaterials. 2004; 25(27): 5893-5903.
70. Kaneda MM, Sasaki Y, Lanza GM, Milbrandt J, Wickline SA. Mechanisms of nucleotide trafficking during siRNA delivery to endothelial cells using perfluorocarbon nanoemulsions. Biomaterials. 2010; 31(11): 3079-3086.
71. del Pozo-Rodríguez A, Delgado D, Solinís MA, Gascón AR. Lipid nanoparticles as vehicles for macromolecules: nucleic acids and peptides. Recent Pat Drug Deliv Formul. 2011; 5(3): 214-226.
72. Teeranachaideekul V, Müller RH, Junyaprasert VB. Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)-effects of formulation parameters on physicochemical stability. Int J Pharm. 2007; 340(1-2): 198-206.
73. Müller R, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm. 2000; 50(1): 161-177.
74. del Pozo-Rodríguez A, Solinís MA, Gascón AR, Pedraz JL. Short-and long-term stability study of lyophilized solid lipid nanoparticles for gene therapy. Eur J Pharm Biopharm. 2009; 71(2): 181-189.
75. Beloqui A, Solinís MA, Delgado A, Evora C, del Pozo-Rodríguez A, Rodríguez-Gascón A. Biodistribution of nanostructured lipid carriers (NLCs) after intravenous administration to rats: influence of technological factors. Eur J Pharm Biopharm. 2013; 84(2): 309-314.
76. del Pozo-Rodríguez A, Delgado D, Solinís MA, Gascón AR, Pedraz JL. Solid lipid nanoparticles: formulation factors affecting cell transfection capacity. Int J Pharm. 2007; 339(1-2): 261-268.
77. Delgado D, del Pozo-Rodríguez A, Solinís MÁ, Rodríguez-Gascón A. Understanding the mechanism of protamine in solid lipid nanoparticle-based lipofection: the importance of the entry pathway. Eur J Pharm Biopharm. 2011; 79(3): 495-502.
78. Delgado D, Gascón AR, del Pozo-Rodríguez A, et al. Dextran-protamine-solid lipid nanoparticles as a non-viral vector for gene therapy: in vitro characterization and in vivo transfection after intravenous administration to mice. Int J Pharm. 2012; 425(1-2): 35-43.
79. Delgado D, del Pozo-Rodríguez A, Solinís MA, Bartkowiak A, Rodríguez-Gascón A. New gene delivery system based on oligochitosan and solid lipid nanoparticles: 'in vitro' and 'in vivo' evaluation. Eur J Pharm Sci. 2013; 50(3-4): 484-491.
80. Rodríguez-Gascón A, Solinis MA, del Pozo-Rodríguez A, Delgado D, Pedraz JL, inventors. University of the Basque Country UPV/EHU. Lipid nanoparticles for gene therapy. US 20120183589 A1. 2012.
81. Rodríguez-Gascón A, Solinis MA, del Pozo-Rodríguez A, Delgado D, Fernandez E, inventors. Lipid nanoparticles for treating ocular diseases. University of the Basque Country UPV/EHU and Universidad Miguel Hernández de Elche. WO 2012085318 A1. 2012.
82. Ruiz de Garibay AP, Delgado D, Del Pozo-Rodríguez A, Solinís MÁ, Gascón AR. Multicomponent nanoparticles as nonviral vectors for the treatment of Fabry disease by gene therapy. Drug Des Devel Ther. 2012; 6: 303-310.
83. Simões S, Filipe A, Faneca H, et al. Cationic liposomes for gene delivery. Expert Opin Drug Deliv. 2005; 2(2): 237-254.
84. Maruyama K, Iwasaki F, Takizawa T, et al. Novel receptor-mediated gene delivery system comprising plasmid/protamine/sugar-containing polyanion ternary complex. Biomaterials. 2004; 25(16): 3267-3273.
85. Rudolph C, Schillinger U, Ortiz A, et al. Application of novel solid lipid nanoparticle (SLN)-gene vector formulations based on a dimeric HIV-1 TAT-peptide in vitro and in vivo. Pharm Res. 2004; 21(9): 1662-1669.
86. del Pozo-Rodríguez A, Pujals S, Delgado D, et al. A proline-rich peptide improves cell transfection of solid lipid nanoparticle-based non-viral vectors. J Control Release. 2009; 133(1): 52-59.
87. Montana G, Bondì ML, Carrotta R, et al. Employment of cationic solid-lipid nanoparticles as RNA carriers. Bioconjug Chem. 2007; 18(2): 302-308.
88. Kofler RM, Aberle JH, Aberle SW, Allison SL, Heinz FX, Mandl CW. Mimicking live flavivirus immunization with a noninfectious RNA vaccine. Proc Natl Acad Sci U S A. 2004; 101(7): 1951-1956.
89. Weiss R, Scheiblhofer S, Roesler E, Ferreira F, Thalhamer J. Prophylactic mRNA vaccination against allergy. Curr Opin Allergy Clin Immunol. 2010; 10(6): 567-574.
90. Kalhoro NH, Veits J, Rautenschlein S, Zimmer G. A recombinant vesicular stomatitis virus replicon vaccine protects chickens from highly pathogenic avian influenza virus (H7N1). Vaccine. 2009; 27(8): 1174-1183.
91. Steitz J, Britten CM, Wölfel T, Tüting T. Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP. TRP2. Cancer Immunol Immunother. 2006; 55(3): 246-253.
92. Yu H, Babiuk LA, van Drunen Littel-van den Hurk S. Immunity and protection by adoptive transfer of dendritic cells transfected with hepatitis C NS3/4A mRNA. Vaccine. 2007; 25(10): 1701-1711.
93. Pan CH, Greer CE, Hauer D, et al. A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles. J Virol. 2010; 84(8): 3798-3807.